(Reuters) – Regeneron Pharmaceuticals Inc beat Wall Street estimates for quarterly profit on Thursday, driven by strong demand for eczema treatment Dupixent.
The company reported adjusted profit of $10.24 per share for the second quarter, topping analysts’ average estimates of $9.84, according to Refinitiv data.
Advertisement
(Reporting by Khushi Mandowara in Bengaluru)
